Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2004-04-21
2011-11-08
Nguyen, Quang (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C514S04400A, C536S023720
Reexamination Certificate
active
08052966
ABSTRACT:
Methods and compositions for producing targeted delivery vectors are provided. Such vectors are useful for treating neoplastic disorders. Also provided are protocols for administering targeted delivery vectors in a clinical setting such that a therapeutic effect is achieved.
REFERENCES:
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5354674 (1994-10-01), Hodgson
patent: 5512421 (1996-04-01), Burns et al.
patent: 5591624 (1997-01-01), Barber et al.
patent: 5643770 (1997-07-01), Mason et al.
patent: 5661023 (1997-08-01), Hrinda et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5800811 (1998-09-01), Hall et al.
patent: 6004798 (1999-12-01), Anderson et al.
patent: 6281010 (2001-08-01), Gao et al.
patent: 6818439 (2004-11-01), Jolly et al.
patent: 7060811 (2006-06-01), Aldaz et al.
patent: 7347998 (2008-03-01), Hall et al.
patent: 7708986 (2010-05-01), Gordon et al.
patent: 2002/0177571 (2002-11-01), Gordon et al.
patent: 2003/0027818 (2003-02-01), Redmond et al.
patent: 2006/0251627 (2006-11-01), Gordon
patent: 2007/0224188 (2007-09-01), Allan et al.
patent: 2007/0225603 (2007-09-01), Jackson
patent: 2008/0119572 (2008-05-01), Owens et al.
patent: 2009/0123428 (2009-05-01), Hall et al.
patent: 2595915 (1998-08-01), None
patent: 0334 301 (1998-09-01), None
patent: WO 95/25789 (1995-09-01), None
patent: WO 96/30504 (1996-10-01), None
patent: WO 96/39430 (1996-12-01), None
patent: WO-98-01582 (1998-01-01), None
patent: WO 98/44938 (1998-10-01), None
patent: WO 98/51700 (1998-11-01), None
patent: 01/64870 (2001-09-01), None
Dang et al. Gene therapy and translational cancer research. Clin. Cancer Res. 5:471-474,1999.
Romano et al. Latest developments in gene transfer technology: Achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18:19-39, 2000.
Verma et al. Gene therapy: Twenty-first century medicine. Annu. Rev. Biochem. 74:711-738, 2005.
Goncalves M. A concise peer into the background, initial thoughts and practices of human gene therapy. BioEssays 27:506-517, 2005.
Gardlik et al. Vectors and delivery systems in gene therapy. Med. Sci. Monit. 11:RA110-121, 2005.
Gordon et al. Inhibition of mestastatic tumor gowth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 cosntruct. Cancer Res. 3343-3347, 2000.
Lenz et al. Tumor site-specific phase I/II evaluationof the safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negtive cyclin G1 (dnG1) construct as treatment for colorectal carcinoma metastatic to liver. Human Gene Therapy 12:1563-1565, Aug. 2001.
Anderson W.F., “Human Gene Therapy,”Nature, vol. 392 (supp), pp. 25-30, 1998.
Arap et al., “Cancer Treatment By Targeted Drug Delivery To Tumor Vasculature In A Mouse Model”,Science, vol. 279, pp. 377-380, 1998.
Asher, et al., “Murine Tumor Cells Transduced with the Gene for Tumor Necrosis Factor-α”,The Journal of Immunology, vol. 146, No. 9, pp. 3227-3234, May 1, 1991.
Blankenstein, et al., “Tumor Suppression after Tumor Cell-targeted Tumor Necrosis Factor α Gene Transfer”,The Journal of Experimental Medicine, vol. 173, No. 5, pp. 1047-1052, May 1991.
Borrello, et al., “A Universal Granulocyte-Macrophage Colony-Stimulating Factor-Producing Bystander Cell Line for Use in the Formulation of Autologous Tumor Cell-Based Vaccines”,Human Gene Therapy, vol. 10, No. 12, pp. 1983-1991, Aug. 10, 1999.
Cosset et al., “Retroviral Targeting by Envelopes Expressing an N-Terminal binding domain”,J Virol, vol. 69, pp. 6314-6322, 1995.
Cosset et al., “Targeting Retrovirus Entry”,Gene Therapy, vol. 3, pp. 946-956, 1996.
Coze, et al., “Characteristics and Immunomodulatory Properties of Human Neuroblastoma Cells after Retrovirus-Mediated Gene Transfer of the Cytokine Genes IL-2 and IFN-γ”,Transgenics, vol. 1, No. 6, pp. 585-595, 1995.
Dranoff, et al., “Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity”,Proceedings of the National Academy of Sciences, vol. 90, No. 8, pp. 3539-3543, Apr. 15, 1993.
El Kamar et al., “Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative Care”,The Oncologist, vol. 8, pp. 18-34, 2003.
Fearon, et al., “Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response”,Cell, vol. 60, No. 3, pp. 397-403, Feb. 9, 1990.
Fong, et al., “The Use and Development of Retroviral Vectors to Deliver Cytokine Genes for Cancer Therapy”,Critical Reviews in Therapeutic Drug Carrier Systems, vol. 17, No. 1, pp. 1-60, 2000.
Foreman, et al., “Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication”,British Journal of Cancer, vol. 67, pp. 933-938, 1993.
Gansbacher, et al., “Retroviral lymphokine gene transfer induced secretion of Interleukin-2 (IL-2) or Interferon-gamma (IFN-γ) by human melanoma cells”, Eighty-Second annual meeting of the American Association for Cancer Research Proceedings, Houston, Texas, vol. 32, 1514 (Abstract) May 15-18, 1991.
Gilboa, “Immunotherapy of Cancer with Genetically Modified Tumor Vaccines”, Seminars in Oncology, vol. 23, No. 1, pp. 101-107, Feb. 1996.
Golumbek, “Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4”,Science, vol. 254, pp. 713-716, Nov. 1, 1991.
Gordon, et al., “Inhibition of Metastatic Tumor Growth in Nude Mice by Portal Vein Infusions of Matrix-targeted Retroviral Vectors Bearing a Cytocidal Cyclin G1 Construct”,Cancer Research, vol. 60, No. 13, pp. 3343-3347, Jul. 1, 2000.
Gordon, E.M. et al., “Capture and expansion of bone marrow-derived mesenchymal progenitor cells with a transforming growth factor-β1—von Willebrand's factor fusion protein for retrovirus-mediated delivery of coagulation factor IX”, Jul. 20, 1997,Human Gene Therapy, vol. 8, pp. 1385-1394.
Gordon, et al., “Systemic Administration of a Matrix-Targeted Retroviral Vector is Efficacious for Cancer Gene Therapy in Mice”,Human Gene Therapy, vol. 12, No. 2, pp. 193-204, Jan. 20, 2001.
Gordon et al., “Genetic Engineering of Targeted Retroviral Vectors”, Curiel DT, Douglass JT, eds. Vector Targeting Strategies for Therapeutic Gene Delivery, New York, NY Wiley-Liss, Inc., pp. 293-320, 2002.
Guinan, et al., “Pivotal Role of the B7:CD28 Pathway in Transplantation Tolerance and Tumor Immunity”,Blood, vol. 84, No. 10., pp. 3261-3282, Nov. 15, 1994.
Hall et al., “Targeting Retroviral Vectors to Vascular Lesions by Genetic Engineering of the MoMuIV gp70 Envelope Protein”, Human Gene Therapy 8, pp. 2183-2192, 1997.
Hall, et al., “Molecular Engineering of Matrix-Targeted Retroviral Vectors Incorporating a Surveillance Function Inherent in von Willebrand Factor”,Human Gene Therapy, vol. 11. No. 7, pp. 983-993, May 1, 2000.
Handgretinger et al., “Interferon-Gamma Upregulates the Susceptibility of Human Neuroblastoma Cells to Interleukin-2-Activated Natural Killer Cells”,Natural Immunity and Cell Growth Regulation, vol. 8, pp. 189-196, Jul./Aug. 1989.
Hock, et al., “Interleukin 7 Induces CD4+T Cell-dependent Tumor Rejection”,The Journal of Experimental Medicine, vol. 174, No. 6, pp. 1291-1298, Dec. 1, 1991.
Hu et al., “Design of Retroviral Vectors and Helper Cells for Gene Therapy”,Pharmacology Reviews, vol. 52, No. 4, pp. 493-511, 2000.
Jaffee, “Immunotherapy of Cancer”,Annals of the New York Academy of Sciences, vol. 886, pp.67-72.
Kasahara et al., “Tissue-Specific Targeting of Retroviral Vectors Through Ligand-Receptor interactions”Sci
Gordon Erlinda M.
Hall Frederick L.
Nguyen Quang
University of Southern California
Wilson Sonsini Goodrich & Rosati
LandOfFree
Methods and compositions for treating metastatic cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating metastatic cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating metastatic cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4288898